Know Cancer

or
forgot password

A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens


Phase 3
55 Years
N/A
Not Enrolling
Both
Acute Myelogenous Leukemia

Thank you

Trial Information

A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens


After screening and eligibility assessment, patients were randomized (in a 1:1 ratio) to
receive either clofarabine or matching placebo, in addition to cytarabine. Randomization
was stratified by remission status following the first induction regimen (CR1): no
remission [i.e., CR1 = refractory] or remission <6 months vs remission ≥6 months. During
randomization by interactive voice response system (IVRS), there were 10 participants
misclassified to the CR1 <6 months stratum and 12 participants misclassified to CR1 ≥6
months stratum. The error did not affect the participants' treatment, only the
stratification. Due to the misclassification, outcomes that used strata in their analysis
were analyzed twice: once with the 'randomized stratification' which includes the
misclassification and once with the 'calculated stratification' in which participants appear
in the 'correct' strata.

Two clinical study reports were written for this study.

1. Clinical study report dated 7 April 2011 includes the entire treatment period of all
participants plus much of the follow-up. At that time, 33 participants in the
Clofarabine+cytarabine group and 29 participants in the placebo+cytarabine group were
still being follow-up post treatment. Results were reported on clinicaltrials.gov in
August 2011. Outcomes that used strata reported the 'calculated strata' on
clinicaltrials.gov.

2. Clinical study report dated 9 July 2012 includes all patient treatment experience plus
all long-term follow-up (a minimum of 2 years from the end of treatment or until the
patient died). The study was completed at that time. Outcomes that used strata
reported the 'randomized strata' on clinicaltrials.gov. AE records on
clinicaltrials.gov reflect the final database.

Outcomes that changed between the two clinical study reports due to the additional long-term
follow-up data are reported twice on clinicaltrials.gov (once from each clinical study
report) and the appropriate report date is included in the outcome description. Outcomes
from the 9 July 2012 report represent more complete data.


Inclusion Criteria:



- Have a diagnosis of Acute Myelogenous Leukemia (AML) according to World Health
Organization (WHO) classification

- Relapsed after receiving up to 2 prior induction regimens (i.e. first or second
relapse)or are refractory to not more than one prior combination chemotherapy
induction regimen

- Be ≥ 55 years of age

- Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2

- Be able to comply with study procedures and follow-up examinations

- Be nonfertile or agree to use birth control during the study through the end of
treatment visit and for at least 90 days after the last dose of study drug

- Have adequate liver and renal function as indicated by certain laboratory values

Exclusion Criteria:

- Received previous treatment with clofarabine

- Received bolus, intermediate or high-dose cytarabine as induction therapy unless
certain remission criteria are met

- Have received a hematopoietic stem cell transplant (HSCT) within the previous 3
months

- Have moderate or severe graft versus host disease (GVHD), whether acute or chronic

- Are receiving any other chemotherapy or investigational therapy. Patients must have
been off prior AML therapy for at least 2-6 weeks prior to entering study.

- Have a psychiatric disorder that would interfere with consent, study participation,
or follow-up

- Have an active, uncontrolled infection

- Have any other severe concurrent disease, or have a history of serious organ
dysfunction or disease involving the heart, kidney, liver, or other organ system

- Have been diagnosed with another malignancy, unless disease-free for at least 5
years; patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical
intraepithelial neoplasia, regardless of the disease-free duration, are eligible for
this study if definitive treatment for the condition has been completed; patients
with organ-confined prostate cancer with no evidence of recurrent or progressive
disease are eligible if hormonal therapy has been initiated or the malignancy has
been surgically removed.

- Have clinical evidence suggestive of central nervous system (CNS) involvement with
leukemia unless lumbar puncture confirms absence of leukemic blasts in the
cerebrospinal fluid(CSF)

- Known HIV positivity

- Are pregnant or lactating

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)

Outcome Description:

Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 calculated strata. OS was defined as the number of months from date of randomization until date of death due to any cause.

Outcome Time Frame:

Day 1 (randomization) up to approximately 4 years

Safety Issue:

No

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Genzyme

Authority:

United States: Food and Drug Administration

Study ID:

CLO34100405

NCT ID:

NCT00317642

Start Date:

August 2006

Completion Date:

January 2012

Related Keywords:

  • Acute Myelogenous Leukemia
  • acute myelogenous leukemia
  • acute myeloid leukemia
  • relapsed AML
  • refractory AML
  • clofarabine
  • cytarabine
  • CLO341
  • clolar
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location

Arizona Cancer CenterTucson, Arizona  85724
MD Anderson Cancer CenterHouston, Texas  77030-4096
UCLA School of MedicineLos Angeles, California  900121973
Medical University of South CarolinaCharleston, South Carolina  29425-0721
Beth Israel Deaconess Medical CenterBoston, Massachusetts  02215
Medical College of WisconsinMilwaukee, Wisconsin  53226
Rush University Medical CenterChicago, Illinois  60612-3824
University of Kansas Medical CenterKansas City, Kansas  66160-7353
University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma  73104
Rocky Mountain Cancer CenterDenver, Colorado  80218
Vanderbilt University Medical CenterNashville, Tennessee  37232-2516
Evanston Northwestern HealthcareEvanston, Illinois  60201
Harold Alfond Center for Cancer CareAugusta, Maine  04330
Duke University Medical CenterDurham, North Carolina  27710
Northwestern UniversityChicago, Illinois  60611
Scripps Cancer CenterLa Jolla, California  92037
University of Colorado Health Science CenterAurora, Colorado  80010-0510
Roswell Park Cancer CenterBuffalo, New York  14263
Dartmouth Hitchcock Medical CenterLebanon, New Hampshire  03756
Gabrail Cancer CenterCanton, Ohio  44718
Louisiana State University Health Science CenterNew Orleans, Louisiana  70112
Josephine Ford Cancer CenterDetroit, Michigan  48202
Wake Forest University School of MedicineWinston-Salem, North Carolina  27157-1023
Oregon Health Science UniversityPortland, Oregon  97239
Mt. Sinai School of MedicineNew York, New York  10029
The Cancer Center at Hackensack University Medical CenterHackensack, New Jersey  07601
Sarah Cannon Research InstituteNashville, Tennessee  37203
University of Kentucky, Markey Cancer CenterLexington, Kentucky  40536-0093
Cancer Care Centers of South TexasSan Antonio, Texas  78229
Stanford Comprehensive Cancer CenterStanford, California  94305
New York Medical CenterNew York, New York  10016
University of Texas Health Sciences CenterSan Antonio, Texas  
University of Tennessee Medical CenterKnoxville, Tennessee  37920
Mayo Clinical HospitalScottsdale, Arizona  
University of Arkansas for Medical Sciences, Arkansas Cancer Research CenterLittle Rock, Arkansas  
University of Southern California, Kenneth Norris Cancer CenterLos Angeles, California  
Cancer Center of Central ConnecticutSouthington, Connecticut  
Mecklenburg Medical GroupCharlotte, North Carolina  
UT Southwestern Medical Center, Simmons Comprehensive Cancer CenterDallas, Texas  
University of Utah - Huntsman Cancer InstituteSalt Lake City, Utah  
West Virginia University Hospitals, Mary Babb Randolph Cancer CenterMorgantown, West Virginia